John W. Poyhonen
Net Worth

Last updated:

What is John W. Poyhonen net worth?

The estimated net worth of Mr. John W. Poyhonen is at least $5,786,823 as of 13 Apr 2023. He owns shares worth $23,223 as insider and has received compensation worth at least $5,763,600 in Heron Therapeutics, Inc..

What is the salary of John W. Poyhonen?

Mr. John W. Poyhonen salary is $720,450 per year as Pres & Chief Commercial Officer in Heron Therapeutics, Inc..

How old is John W. Poyhonen?

Mr. John W. Poyhonen is 65 years old, born in 1960.

What stocks does John W. Poyhonen currently own?

As insider, Mr. John W. Poyhonen owns shares in one company:

Company Title Shares Price per share Total value
Heron Therapeutics, Inc. (HRTX) Pres & Chief Commercial Officer 18,143 $1.28 $23,223

What does Heron Therapeutics, Inc. do?

Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; HTX-019, an investigational agent for the prevention of postoperative nausea and vomiting; and HTX-034 for postoperative pain management, as well as is in Phase Ib/II clinical study in patients undergoing bunionectomy. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.

HRTX logo
HRTX
Heron Therapeutics, Inc.
$1.28

John W. Poyhonen insider trading

Heron Therapeutics, Inc.

Transaction Date Security Shares Price per share Total value Source
Option
Common Stock 1,250 N/A N/A
Option
Restricted Stock Units 1,250 N/A N/A
Option
Common Stock 4,564 N/A N/A
Option
Restricted Stock Units 4,564 N/A N/A
Option
Common Stock 1,250 N/A N/A
Option
Restricted Stock Units 4,564 N/A N/A
Option
Restricted Stock Units 1,250 N/A N/A
Option
Common Stock 4,564 N/A N/A
Option
Common Stock 4,564 N/A N/A
Option
Common Stock 1,250 N/A N/A
Option
Restricted Stock Units 4,564 N/A N/A
Option
Restricted Stock Units 1,250 N/A N/A
Option
Common Stock 1,250 N/A N/A
Option
Restricted Stock Units 1,250 N/A N/A
Option
Restricted Stock Units 4,564 N/A N/A
Option
Common Stock 4,564 N/A N/A
Option
Common Stock 1,250 N/A N/A
Option
Restricted Stock Units 4,564 N/A N/A
Option
Restricted Stock Units 1,250 N/A N/A
Option
Common Stock 4,564 N/A N/A
Option
Common Stock 4,564 N/A N/A
Option
Restricted Stock Units 1,250 N/A N/A
Option
Common Stock 1,250 N/A N/A
Option
Restricted Stock Units 4,564 N/A N/A
Option
Restricted Stock Units 1,250 N/A N/A
Option
Common Stock 1,250 N/A N/A
Option
Restricted Stock Units 1,250 N/A N/A
Option
Common Stock 1,250 N/A N/A
Option
Common Stock 1,250 N/A N/A
Option
Restricted Stock Units 1,250 N/A N/A
Option
Restricted Stock Units 1,250 N/A N/A
Option
Common Stock 1,250 N/A N/A
Purchase
Common Stock 5,143 $17.5 $90,003
Purchase
Common Stock 3,000 N/A N/A
Purchase
Common Stock 10,000 N/A N/A

Heron Therapeutics key executives

Heron Therapeutics, Inc. executives and other stock owners filed with the SEC: